COLL Q4 2025 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$205M+12.9% YoY

Gross Profit

$128M62.5% margin

Operating Income

$59M28.8% margin

Net Income

$17M8.3% margin

EPS (Diluted)

$0.46

QoQ Revenue Growth

-1.9%

Cash Flow

Operating Cash Flow

$123M

Free Cash Flow

$122M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$1.4B

Stockholders' Equity

$302M

Cash & Equivalents

$251M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$205M	$182M	+12.9%
Gross Profit	$128M	$98M	+30.6%
Operating Income	$59M	$38M	+55.4%
Net Income	$17M	$13M	+35.3%

Revenue Segments

Belbuca

$59M38%

Xtampza ER

$49M31%

Nucynta IR

$29M19%

Nucynta ER

$19M12%